2Seventy Bio Investor Relations Material
Latest events
Q3 2024
2Seventy Bio
Q1 2025
7 May, 2025
Q4 2024
25 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 2Seventy Bio Inc
Access all reports
2Seventy Bio Inc. (NASDAQ: TSVT) is a biotechnology company specializing in cell and gene therapy with a focus on developing and commercializing treatments for cancer within the United States. The company's research and development efforts are centered on advancing a pipeline of chimeric antigen receptor-T cell (CAR-T) product candidates, including idecabtagene vicleucel (ide-cel or Abecma) and bb21217, aimed at treating multiple myeloma. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
TSVT
Country
🇺🇸 United States